Skip to main content

Table 3 Comparison of patients with echocardiography and patients with missing examination after 12 months

From: Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)

Variable

12 months dropouts [n = 21]

12 months completers [n = 50]

 
 

Mean ± standard deviation or n and (%)

95% CI (mean)

median and interquartile ranges

 

Mean ± standard deviation or n and %

95% CI (mean)

median and interquartile ranges

 

N

lower limit

upper limit

N

lower limit

upper limit

p-value

Demographics

 Age [years]

21

59.5 ± 11.66

54.2

64.8

56 [49; 71]

50

59.0 ± 14.2

54.9

63.0

60 [51; 71]

0.845

 Height [cm]

21

170.1 ± 10.95

165.1

175.1

172 [163; 175]

50

166.5 ± 9.3

163.9

169.2

168 [160; 173]

0.267

 Weight [kg]

21

78.7 ± 12.5

73.0

84.4

75.0 [71; 88]

50

76.2 ± 19.3

70.7

81.6

71 [65; 85]

0.196

 BMI [kg/m2]

21

27.2 ± 3.5

25.6

28.8

26.8 [25.7; 28.4]

50

27.3 ± 5.6

25.7

28.9

26.0 [23.3; 30.0]

0.575

 gender [female n (%)]

 

11 (52.4%)

    

27 (54.0%)

    

Pulmonary hypertension etiology

 Idiopathic PAH

 

3 (14.3%)

    

11 (22.0%)

    

 Other PAH

 

6 (28.6%)

    

12 (24.0%)

    

 Chronic thromboembolic pulmonary hypertension

 

12 (57.1%)

    

27 (54.0%)

    

WHO functional class

 II

 

6 (28.6%)

    

11 (22.0%)

    

 III

 

15 (71.4%)

    

39 (78.0%)

    

Pulmonary hypertension targeted treatment

 treatment naÏve

 

2 (33.3%)

    

35 (70%)

    

 Endothelin-Receptor-Antagonist

 

2 (33.3%)

    

12 (24%)

    

 Phosphodiesterase-5-inhibitor

 

2 (33.3%)

    

3 (6%)

    

 Oxygen

 

2 (33.3%)

    

5 (10%)

    

Vital signs

 Systolic Blood Pressure [mmHg]

21

116 ± 12

110

121

110 [110; 125]

50

114 ± 14

110

121

110 [110; 125]

0.378

 Diastolic Blood Pressure [mmHg]

21

75 ± 10

71

80

76 [70; 80]

50

71 ± 10

68

73

70 [64; 80]

0.040

 Heart Rate [bpm]

21

79 ± 9

75

83

80 [72; 84]

50

81 ± 11

78

84

80 [73; 88]

0.645

Clinical parameters

 NTproBNP [pmol/L]

11

183.7 ± 243.4

20.2

347.2

76 [29.6; 217.4]

30

125.3 ± 228.4

40.0

210.6

42.2 [17.4; 144.8]

0.471

 6-min walking distance [meters]

18

338.5 ± 99.9

288.8

388.2

362 [270; 406]

50

366.4 ± 88.1

341.3

391.4

370 [301; 420]

0.440

Hemodynamics measured by right heart catheter

 mean PAP [mmHg]

13

48.6 ± 54.1

43.0

54.1

47 [45; 57]

32

45.1 ± 10.1

41.5

48.8

43.5 [37.8; 53.3]

0.215

 Pulmonary Vascular Resistance [dyn*sec*cm− 5]

13

781.3 ± 259.3

624.6

938.0

747.8 [615.4; 904.3]

32

668.0 ± 289.3

563.8

772.3

563.1 [495.2; 789.7]

0.112

 Cardiac Index [L/min/m2]

13

2.4 ± 0.5

2.1

2.7

2.5 [2.2; 2.7]

32

2.6 ± 0.5

2.4

2.7

2.6 [2.4; 2.8]

0.276

 Cardiac Output [L/min]

13

4.6 ± 0.9

4.0

5.1

4.6 [4.3; 5.2]

32

4.8 ± 1.1

4.3

5.2

4.6 [4.3; 8.2]

0.861

 Pulmonary Arterial Wedge Pressure [mmHg]

13

6.0 ± 2.7

4.4

7.6

6 [5; 8]

32

7.9 ± 2.8

6.9

8.9

7 [6; 10]

0.052

  1. CI confidence interval, BMI Body mass index, NTproBNP N-terminal fragment of pro brain natriuretic peptide, PAP pulmonary arterial pressure